VasThera’s Dr. Sang Won Kang to Present at the 2022 BIO International Convention

VasThera announced today that Dr. Sang Won Kang, CEO of VasThera, presented at the 2022 BIO International Convention June 13-16, 2022, in San Diego, California. Dr. Sang Won Kang spoke to senior biotech executives, business development leaders, and investors on De novo Drug design for Cardiovascular disease, especially VTA-04 for pulmonary arterial hypertension.

The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders. The four-day, in-person event includes networking, programming, and partnering opportunities.

Dr. Kang have been studying the redox signal network over 20 years. Related to the arterial vessels, the core science has been published the top journals, Nature, Molecular cell and Circulation. Based on this achievement, Dr. Kang founded VasThera in 2018. Recently, VasThera finished the series B investment, around 20 million us dollars.

According to the global data report, the global pulmonary arterial hypertension(PAH) market value was approximately $ 4.5B in 2019, and it will be grown by $ 7.5B in 2029. PAH patients are suffering because the sequential combination therapy depending on disease progress. VasThera’s VTA-04 program suggests the disease modifying treatment option to pulmonary arterial hypertension patients which required high unmet medical needs.

About VASTHERA

VasThera is an innovative pharmaceutical company, located in Korea. VasThera develops the first-in-class therapeutics targeting the vascular diseases, with a primary focus in pulmonary arterial hypertension (PAH) and also oncology and neurodegenerative disease. VasThera is the only company in the world possessing novel small molecules capable of replacing the redox enzymes that regulate receptor signaling.

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Good Day BIO is the only daily newsletter at the intersection of biotech, politics, and policy. Subscribe here.